Crystalys Therapeutics
Transforming care for people living with gout.
Crystalys Therapeutics was founded in 2025, is headquartered in San Diego, United States, lists 11–50 employees, and has $335.0M in recorded funding across 2 rounds.
- Headquarters
- San Diego, California
- Employees
- 11–50
- Founded
- 2025
- Business Model
- B2B
- Website
- crystalystx.com
- Total Funding
- $335.0M
- Last Round
- $130.0M Series BJul 2026
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 12 investors for this company. The full record is or through the API.
About
Crystalys Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on transforming the treatment of gout — a disease that affects an estimated 10 million Americans yet remains poorly served by existing therapies. The company's lead candidate, dotinurad, is a next-generation URAT1 inhibitor that addresses difficult-to-treat and refractory gout cases that cannot be adequately managed with generic allopurinol. Crystalys launched in September 2025 with a $205 million Series A financing round and is currently conducting Phase 2 clinical trials, with first patients dosed in May 2026. The company was founded by an experienced team with deep background in uric acid biology and URAT1 inhibitor mechanisms.
Summary
Crystalys Therapeutics is a Biotech company based in San Diego, United States, founded in 2025. It lists 11–50 employees. It has raised $335.0M in total across 2 rounds, most recently a $130.0M Series B round in Jul 2026. Investors include Novo Holdings A/S, SR One and Catalys Pacific.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jul 2026
Sign up to see all 2 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Novo Holdings A/S
2 rounds
SR One
2 rounds
Catalys Pacific
2 rounds
Frazier Life Sciences
1 round
Wellington Management
2 rounds
HBM Healthcare Investments
1 round
Soleus Capital
1 round
Cormorant
1 round
HBM Partners
1 round
Cormorant Asset Management
1 round
Frazier Healthcare
1 round
Lightstone Ventures
1 round
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/crystalys-therapeutics"><img src="https://indexed.vc/api/badge/company/crystalys-therapeutics" alt="Crystalys Therapeutics on Indexed.vc" width="260" height="76" /></a>